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The paper published by Henrotin et al. [1] reported the
results from a double-blind multi-center randomized
placebo controlled study of bio-optimized Curcuma
longa (BCL) extract in patients with symptomatic knee
osteoarthritis (OA). This bio-optimized curcuma extract
is a widely used food supplement.
We received two letters that highlight six potential
shortcomings in the design of this study and the inter-
pretation of the results. As the content of these letters is
virtually similar, we decided to answer both letters in
one document.
The first shortcoming was about the timeline of study
registration. This prospective study was recorded in
September 2016 while the first patient was enrolled in
2014. In contrast with medicinal products and biologics
and medical devices, there are no legal requirements for
registry of a clinical trial investigating dietary supple-
ments. However, in order to comply with the Declar-
ation of Helsinki and WHO recommendations, for the
sake of transparency, and for scientific publication, the
trial was indeed registered on Clinical trial.gov on
September 13, 2016 (NCT02909621).
The second point concerns the selection of the co-
primary endpoints. A particularity of this study was the
use of two unusual co-primary endpoints. One endpoint
was the Patient Global Assessment of Disease Activity
(PGADA) and the other the serum levels of Coll2-1, a
specific peptide and epitope of type II collagen and
considered as a biomarker of cartilage degradation. In-
deed, these co-primary endpoints are not recommended
by any regulatory agency, but they were defined based
on the results obtained in a previous pilot study [2].
Importantly, the design of this study was exploratory
and gave interesting data about innovative biomarkers.
Further, this approach was in line with OARSI-FDA
consortium recommendation 23 which encouraged the
collection of biological fluids in randomized clinical tri-
als to investigate the metabolic effect of a treatment on
joint tissues and to qualify a biomarker or a cluster of
biomarkers for treatment development and use in the
context of a personalized approach of OA management
[3]. Again, this study has an objective to provide useful
information for the design of a potential larger phase III
study including the sample size estimate, the choice of
the dose, and the selection of primary outcome.
The third point concerns the calculation of the sample
size. The sample size calculation was challenged by the
statistician of the journal and ultimately considered as
correctly addressed. The sample size was calculated
following the highest standard. Indeed, the sample
size was defined according the International Clinical
Harmonization (ICH) E9 guidelines for clinical trials
(ICH E9—see additional file 2 in the original paper).
Sample size considered also the results obtained in a
preceding pilot study [2]. We calculated a sample size
of 150 patients based on a decrease in Coll2-1 biomarker
levels of 44.4 nmol/L with standard deviation of 53 or a
decrease in patient assessment of global disease activity of
21mm with standard deviation of 25 in the treated groups
and no change in the control group, an alpha risk of 5%
that was divided by 2 (2.5%) as a correction for multiple
testing, a power of 85%, and a drop-out rate of 15%. Taken
individually, the two co-primary endpoints lead to the
same sample size.
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The fourth comment questioned the role of the 6-
month test results. As explained in the original paper,
the 6-month follow-up was exploratory and failed to give
additional relevant information. For that reason, the 6-
month data were not reported in the paper but pre-
sented in supplementary tables.
Fifth, only post hoc analyses reported a difference
compared to the placebo group, which is methodologic-
ally disputable in a study that fails to meet the primary
endpoints. Post hoc analysis is commonly performed in
the literature, even in a negative study, and cannot be
considered as methodologically disputable. Of course,
results have to be interpreted and discussed in consider-
ation of this point.
The final shortcoming was about the safety of the
product. As indicated in the original paper, 18.5% of the
subjects dropped out of the trial because of adverse
events in the high dose group. Consequently, the authors
of the study suggested that the recommended dose of
BCL was two caps twice a day. This observation met one
the objectives of the study, which was to identify the po-
tentially most effective and safe dose of BCL.
In conclusion, we would like to point out that this
study was performed according to the International
Council for Harmonisation of Technical Requirements
for Pharmaceuticals for Human use (ICH E6) and inter-
pretation consistent with the results, balancing benefits
and harms, and considering other relevant evidence.
We believe that the paper conclusion “efficacy analysis
suggested positive trends for measurements of PGADA
and serum levels of a biomarker and a significant de-
crease of pain in knee OA” is reasonably well balanced.
It has not escaped our attention that the authors of these
letters fail to disclose their potential conflicts of interest.
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